MT-501 for Inflammatory Bowel Disease
(ASCEND-IBD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment, MT-501, for individuals with inflammatory bowel disease (IBD), specifically Crohn's Disease or Ulcerative Colitis. The main goal is to assess the safety and effectiveness of MT-501 for these conditions. Participants must have moderately to severely active Crohn's Disease or Ulcerative Colitis, experiencing frequent and intense symptoms that impact daily life. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to benefit from innovative therapy.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop your current medications, but it mentions that participants must meet drug stabilization requirements. This might mean you need to be on a stable dose of your current medications before joining the trial.
Is there any evidence suggesting that MT-501 is likely to be safe for humans?
Research shows that MT-501 is being tested for safety and effectiveness in individuals with moderate to severe Crohn's Disease and Ulcerative Colitis, both types of inflammatory bowel disease (IBD). Previous studies have found that MT-501 is generally well-tolerated. Most participants did not experience serious side effects, though some reported mild to moderate effects like headaches or mild stomach discomfort, which are common with many treatments.
MT-501 is currently in a Phase 2 trial, indicating it has already passed initial safety tests in humans. This phase focuses more on the treatment's effectiveness and further examines its safety in a larger group. Since everyone can react differently to treatments, discussing any concerns with a healthcare provider is important.12345Why are researchers excited about this trial's treatments?
Researchers are excited about MT-501 because it offers a novel approach to treating Inflammatory Bowel Disease, including Ulcerative Colitis and Crohn's Disease. Unlike traditional treatments, which often rely on suppressing the immune system, MT-501 targets specific inflammatory pathways, potentially reducing side effects and increasing effectiveness. This precision in targeting inflammation may lead to faster symptom relief and improved long-term outcomes for patients.
What evidence suggests that MT-501 might be an effective treatment for IBD?
Studies have shown that MT-501 may benefit people with inflammatory bowel disease (IBD), including Crohn's Disease and Ulcerative Colitis. Early findings suggest that MT-501 can reduce gut swelling, potentially leading to fewer symptoms. Research indicates that the treatment targets specific body parts responsible for this swelling, possibly offering better disease control than some current treatments. Although more information is needed, early results are promising for those with moderate to severe IBD. Participants in this trial will receive MT-501, with separate study arms focusing on either Crohn's Disease or Ulcerative Colitis.12467
Are You a Good Fit for This Trial?
Adults with moderately to severely active Crohn's Disease or Ulcerative Colitis confirmed by endoscopy and histopathology can join. They must meet drug stabilization requirements and have specific disease activity levels. Excluded are those with CD affecting certain digestive regions, recent severe UC complications, abscesses, recent IV steroid use, imminent surgeries, indeterminate colitis diagnosis, or extensive previous bowel resections.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive multiple investigational drugs for Crohn's Disease or Ulcerative Colitis
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MT-501
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mirador Therapeutics, Inc.
Lead Sponsor